Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7651790 | 0.86 | KMT2A (0.43) | GAAKDM4EGLABRD4NR4A2 | |
| SCHEMBL15798471 | 0.83 | KDM4E (0.51) | GAAKDM4EGLABRD4NR4A2 | |
| SCHEMBL15798719 | 0.81 | KMT2A (0.44) | GAAKDM4EKMT2AMAPTCYP2C9 | |
| SCHEMBL13534290 | 0.81 | MAPT (0.55) | GAAKDM4EGLAKMT2AMAPT | |
| SCHEMBL8672229 | 0.79 | KMT2A (0.45) | GAAKDM4EKMT2AMAPTCYP2C9 | |
| SCHEMBL28945709 | 0.79 | BRD4 (0.54) | GAAKDM4EGLABRD4NR4A2 | |
| SCHEMBL18640363 | 0.79 | KMT2A (0.50) | GAAKDM4EGLABRD4NR4A2 | |
| SCHEMBL23240428 | 0.79 | BRD4 (0.49) | GAAKDM4EBRD4NR4A2KMT2A | |
| SCHEMBL25424962 | 0.76 | KMT2A (0.42) | GAAKDM4EBRD4KMT2AMAPT | |
| SCHEMBL19847432 | 0.75 | ALDH1A1 (0.50) | BRD4KMT2AMAPTTDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | claimed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | claimed |
| EP-3157572-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| EP-3157573-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| CN-106170553-A | Modified nucleic acid molecules and uses thereof | 现代治疗公司 | 2016-11-30 | — | — | CN | claimed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | claimed |
| EP-3080289-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-10-19 | — | — | EP | claimed |
| WO-2015196128-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | claimed |
| EP-2931319-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2015-10-21 | — | — | EP | claimed |
| WO-2015089511-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-06-18 | — | — | WO | claimed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | claimed |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| CN-116064598-B | Nucleic acid vaccine for coronavirus | 苏州艾博生物科技有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-116615472-A | Polymer conjugated lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-1483384-A2 | METHOD FOR OVEREXPRESSION OF ZWITTERIONIC POLYSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20030207403-A1 | Beta-like glycoprotein hormone polypeptide and heterodimer | AMGEN INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2003077863-A2 | METHOD FOR OVEREXPRESSION OF ZWITTERIONIC POLYSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| US-6599716-B1 | Nucleotide sequences coding polypeptide for use in the treatment of cachexia, toxic shock syndrome, inflammatory, bone and tumor dsorders | AMGEN INC. | 2003-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | GAA 455/4885KDM4E 3519/4885GLA 2199/4885 |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | GAA 455/4885KDM4E 3519/4885GLA 2199/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | GAA 554/4885KDM4E 4196/4885GLA 2498/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | GAA 554/4885KDM4E 4196/4885GLA 2498/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | GAA 455/4885KDM4E 3519/4885GLA 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.